Episode Details

Hims & Hers Health (HIMS) just took an absolute beating, shedding nearly 12% in a single session and wiping $600 million off its market cap. The culprit? Panic-selling triggered by a looming class action lawsuit and an FTC probe into billing and privacy practices. But with Q3 earnings days away, projected revenue near $893 million, and a massive new rollout in men's health, is Wall Street overreacting to regulatory noise? In this episode of Implied, we break down whether this steep drop into the $23 range is a toxic red flag or a prime discount ahead of a potential post-earnings rebound.